China Oncology Anti-Cancer Drugs Market Assessment 2020-2026

Table of Contents

1 Report Overview
    1.1 Definition and Specification
    1.2 Report Overview
        1.2.1 Manufacturers Overview
        1.2.2 Regions Overview
        1.2.3 Type Overview
        1.2.4 Application Overview
    1.3 Industrial Chain
        1.3.1 Oncology Anti-Cancer Drugs Overall Industrial Chain
        1.3.2 Upstream
        1.3.3 Downstream
    1.4 Industry Situation
        1.4.1 Industrial Policy
        1.4.2 Product Preference
        1.4.3 Economic/Political Environment
    1.5 SWOT Analysis
2 Market Analysis by Types
    2.1 Overall Market Performance(Volume)
             2.1.1 Chemotherapy (Volume)
             2.1.2 Targeted Therapy (Volume)
             2.1.3 Immunotherapy (Biologic Therapy) (Volume)
             2.1.4 Hormonal Therapy (Volume)
             2.1.5 Others (Volume)
    2.2 Overall Market Performance(Value)
             2.2.1 Chemotherapy (Value)
             2.2.2 Targeted Therapy (Value)
             2.2.3 Immunotherapy (Biologic Therapy) (Value)
             2.2.4 Hormonal Therapy (Value)
             2.2.5 Others (Value)
3 Product Application Market
    3.1 Overall Market Performance (Volume)
             3.1.1 Blood Cancer (Leukaemia) (Volume)
             3.1.2 Breast Cancer (Volume)
             3.1.3 Gastrointestinal Cancer (Volume)
             3.1.4 Respiratory/Lung Cancer (Volume)
             3.1.5 Skin Cancer (Volume)
             3.1.6 Other Cancers (Volume)
4 Manufacturers Profiles/Analysis
    4.1 Amgen
        4.1.1 Amgen Profiles
        4.1.2 Amgen Product Information
        4.1.3 Amgen Oncology Anti-Cancer Drugs Business Performance
        4.1.4 Amgen Oncology Anti-Cancer Drugs Business Development and Market Status
    4.2 AstraZeneca
        4.2.1 AstraZeneca Profiles
        4.2.2 AstraZeneca Product Information
        4.2.3 AstraZeneca Oncology Anti-Cancer Drugs Business Performance
        4.2.4 AstraZeneca Oncology Anti-Cancer Drugs Business Development and Market Status
    4.3 Roche Diagnostics
        4.3.1 Roche Diagnostics Profiles
        4.3.2 Roche Diagnostics Product Information
        4.3.3 Roche Diagnostics Oncology Anti-Cancer Drugs Business Performance
        4.3.4 Roche Diagnostics Oncology Anti-Cancer Drugs Business Development and Market Status
    4.4 GlaxoSmithKline
        4.4.1 GlaxoSmithKline Profiles
        4.4.2 GlaxoSmithKline Product Information
        4.4.3 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Performance
        4.4.4 GlaxoSmithKline Oncology Anti-Cancer Drugs Business Development and Market Status
    4.5 Merck
        4.5.1 Merck Profiles
        4.5.2 Merck Product Information
        4.5.3 Merck Oncology Anti-Cancer Drugs Business Performance
        4.5.4 Merck Oncology Anti-Cancer Drugs Business Development and Market Status
    4.6 Novartis
        4.6.1 Novartis Profiles
        4.6.2 Novartis Product Information
        4.6.3 Novartis Oncology Anti-Cancer Drugs Business Performance
        4.6.4 Novartis Oncology Anti-Cancer Drugs Business Development and Market Status
    4.7 AbbVie
        4.7.1 AbbVie Profiles
        4.7.2 AbbVie Product Information
        4.7.3 AbbVie Oncology Anti-Cancer Drugs Business Performance
        4.7.4 AbbVie Oncology Anti-Cancer Drugs Business Development and Market Status
    4.8 Sanofi
        4.8.1 Sanofi Profiles
        4.8.2 Sanofi Product Information
        4.8.3 Sanofi Oncology Anti-Cancer Drugs Business Performance
        4.8.4 Sanofi Oncology Anti-Cancer Drugs Business Development and Market Status
    4.9 EIMC United Pharmaceuticals
        4.9.1 EIMC United Pharmaceuticals Profiles
        4.9.2 EIMC United Pharmaceuticals Product Information
        4.9.3 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Performance
        4.9.4 EIMC United Pharmaceuticals Oncology Anti-Cancer Drugs Business Development and Market Status
    4.10 Actavis
        4.10.1 Actavis Profiles
        4.10.2 Actavis Product Information
        4.10.3 Actavis Oncology Anti-Cancer Drugs Business Performance
        4.10.4 Actavis Oncology Anti-Cancer Drugs Business Development and Market Status
5 Market Performance for Manufacturers
    5.1 China Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Manufacturers 2014-2020
    5.2 China Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Manufacturers 2014-2020
    5.3 China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
    5.4 China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
    5.5 Market Concentration
6 Regions Market Performance for Manufacturers
    6.1 South China Market Performance for Manufacturers
        6.1.1 South China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.1.2 South China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.1.3 South China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.1.4 South China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.1.5 Market Concentration
    6.2 East China Market Performance for Manufacturers
        6.2.1 East China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.2.2 East China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.2.3 East China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.2.4 East China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.2.5 Market Concentration
    6.3 Southwest China Market Performance for Manufacturers
        6.3.1 Southwest China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.3.2 Southwest China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.3.3 Southwest China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.3.4 Southwest China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.3.5 Market Concentration
    6.4 Northeast China Market Performance for Manufacturers
        6.4.1 Northeast China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.4.2 Northeast China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.4.3 Northeast China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.4.4 Northeast China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.4.5 Market Concentration
    6.5 North China Market Performance for Manufacturers
        6.5.1 North China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.5.2 North China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.5.3 North China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.5.4 North China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.5.5 Market Concentration
    6.6 Central China Market Performance for Manufacturers
        6.6.1 Central China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.6.2 Central China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.6.3 Central China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.6.4 Central China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.6.5 Market Concentration
    6.7 Northwest China Market Performance for Manufacturers
        6.7.1 Northwest China Oncology Anti-Cancer Drugs Sales (K Units) and Share of Manufacturers 2014-2020
        6.7.2 Northwest China Oncology Anti-Cancer Drugs Revenue (M USD) and Share of Manufacturers 2014-2020
        6.7.3 Northwest China Oncology Anti-Cancer Drugs Price (USD/Unit) of Manufacturers 2014-2020
        6.7.4 Northwest China Oncology Anti-Cancer Drugs Gross Margin of Manufacturers 2014-2020
        6.7.5 Market Concentration
7 China  Oncology Anti-Cancer Drugs Market Performance (Sales Point)
    7.1 China Oncology Anti-Cancer Drugs Sales (K Units) and Market Share by Regions 2014-2020
    7.2 China Oncology Anti-Cancer Drugs Revenue (M USD) and Market Share by Regions 2014-2020
    7.3 China Oncology Anti-Cancer Drugs Price (USD/Unit) by Regions 2014-2020
    7.4 China Oncology Anti-Cancer Drugs Gross Margin by Regions 2014-2020
8 Development Trend for Regions (Sales Point)
    8.1 China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.2 South China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.3 East China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.4 Southwest China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.5 Northeast China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.6 North China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.7 Central China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
    8.8 Northwest China Oncology Anti-Cancer Drugs Sales and Growth, Sales Value and Growth Rate2014-2020
9 Upstream Source, Technology and Cost
    9.1 Upstream Source
    9.2 Technology
    9.3 Cost
10 Channel Analysis
    10.1 Market Channel
    10.2 Distributors
11 Consumer Analysis
    11.1 Blood Cancer (Leukaemia) Industry 
    11.2 Breast Cancer Industry 
    11.3 Gastrointestinal Cancer Industry 
    11.4 Respiratory/Lung Cancer Industry 
    11.5 Skin Cancer Industry 
    11.6 Other Cancers Industry 
12 Market Forecast 2021-2026
    12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
        12.1.1 China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
        12.1.2 China Oncology Anti-Cancer Drugs Sales (K Units) and Growth Rate 2021-2026
        12.1.3 South China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.4 East China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.5 Southwest China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.6 Northeast China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.7 North China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.8 Central China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
        12.1.9 Northwest China Oncology Anti-Cancer Drugs Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
        12.2.1 Overall Market Performance
        12.2.2 Chemotherapy
        12.2.3 Targeted Therapy
        12.2.4 Immunotherapy (Biologic Therapy)
        12.2.5 Hormonal Therapy
        12.2.6 Others
    12.3 Sales and Growth Rate Forecast by Application 2021-2026
        12.3.1 Overall Market Performance
        12.3.2 Blood Cancer (Leukaemia)
        12.3.3 Breast Cancer
        12.3.4 Gastrointestinal Cancer
        12.3.5 Respiratory/Lung Cancer
        12.3.6 Skin Cancer
        12.3.7 Other Cancers
    12.4 Price (USD/Unit) and Gross Profit Forecast 
        12.4.1 China Oncology Anti-Cancer Drugs Price (USD/Unit) Trend 2021-2026
        12.4.2 China Oncology Anti-Cancer Drugs Gross Profit Trend 2021-2026
13 Conclusion